anaplastic meningiomas in the WHO classification. 6, 35, 39, 49 Although benign meningiomas (WHO Grade I) are generally slow growing and have a low recurrence rate after gross-total resection (GTR), 27, 45 atypical meningiomas are more locally aggressive and demonstrate more rapid tumor progression. The literature suggests they have a 5-year recurrence rate of approximately 40% in the absence of postoperative radiotherapy. 8, 19, 29, 35 Atypical meningiomas are also associated with significantly increased mortality. Although GTR, when possible, is widely accepted as the standard of care for benign meningiomas, a purely neurosurgical approach may be inadequate for atypical meningiomas. Immediate adjuvant radiotherapy is clearly beneficial for malignant meningiomas, while its role for the atypical subtype is still under debate. Nonetheless, postoperative radiotherapy is frequently chosen in cases of atypical meningiomas, despite the absence of clear consensus that this treatment is indicated. There is ongoing debate as to whether atypical meningiomas should receive radiotherapy or whether this treatment should be limited to incompletely resected cases. 1, 12 Because of their aggressive behavior, atypical meningiomas have an unpredictable outcome, and reported series have included only a few patients. 25, 34, 50 Even after GTR, tumor recurrence has been observed after several years in some 20%-30% of cases. 20, 44 Thus, a reasonable organized therapeutic strategy could be applied if recurrence could be predicted from surgical specimens, and for this reason many authors have investigated the histological indices of proliferative and apoptotic potential in resected tumors, such as bcl-2, 3, 21 proliferating cell nuclear antigen, 3 and Ki 67 cell cycle-specific nuclear antigen.
17,24
From these indices, researchers have attempted to establish the nature of the relationship between histological aggressiveness and the recurrence of these meningiomas. The molecular mechanisms underlying the development and progression of meningiomas remain poorly understood. Nevertheless, alterations in the pathways that regulate cell proliferation must be involved. One of the most important of these is the p16 INK4A (p16)-cyclin-dependent kinase (CDK)-phosphorylated retinoblastoma (pRB) pathway, which is altered in more than 80% of human cancers. 9, 48 The p16 coding gene has been found to be homozygously deleted, mutated, or transcriptionally inhibited by methylation in a large number of different human tumor types. 31, 32, 41 Mice lacking p16 are tumor prone and develop multiple types of cancer, particularly after exposure to carcinogens. 23, 42 Furthermore, RB is functionally inactivated in a range of cancers, either directly by mutations or indirectly through altered expression and/or activity of upstream regulators. 13 As stated above, several studies have focused on the role of cell cycle regulators in various types of cancer progression and development. However, cell cycle regulators have not yet been evaluated in meningioma, especially the atypical subtype.
In the present study, by immunohistochemically analyzing tumor samples obtained during resection, we aimed to determine the prognostic value of certain cell cycle regulators (CDK4, CDK6, p16, p15, p21, p27, pRB protein, and cyclin D1) in predicting the recurrence of atypical meningioma after resection. We also estimated the number of mitoses as well as the immunoreactivity of MIB-1 antigen and p53, which are already known to be proliferative markers for predicting the recurrence of meningioma. In addition, we examined other factors predisposing atypical meningioma to recurrence.
Methods

Patient Collection
The study protocol was approved by the institutional review boards of Samsung Changwon Hospital and Dong-A University Medical Center, and all patients or their families provided written informed consent. We conducted a retrospective case study and clinical review of the 353 meningioma patients who had been surgically treated by Drs. K. H. Kim and Y. Z. Kim at the Samsung Changwon Hospital and by Dr. H. D. Kim at Dong-A University Medical Center in the period from January 2000 to June 2012. All patients had undergone radical surgery and had a tumor sample for histopathological diagnosis. Among these cases, we selected the tumors that met the diagnostic criteria for atypical meningioma, as outlined in the 2007 WHO classification. 38 The following patients were excluded: 1) those with recurrent atypical meningioma after treatment for a previous benign meningioma; 2) those with multiple intracranial meningiomas, because of the difficulty in evaluating treatment response; 3) those with spinal cord meningioma; 4) those who had undergone preoperative radiotherapy for tumor; and 5) those with ≤ 6 months of follow-up due to follow-up loss.
Patient sex, age at the time of surgery, symptoms at diagnosis, tumor location and size, extent of resection, histological grade, use of postoperative radiotherapy, duration of follow-up, and recurrence were retrospectively reviewed for each patient by using the medical records.
Neuroradiological Findings of Atypical Meningiomas
Tumor size was defined as the largest tumor diameter rounded to the nearest centimeter on Gd-enhanced T1-weighted MR images before the initial surgery. Peritumoral edema was estimated by the longest distance from the margin of the tumor on FLAIR images. The locations of tumors were divided into convexity and nonconvexity groups. The extent of resection was categorized as either complete or incomplete. Complete resection was defined as Simpson Grade I or II, and incomplete resection was defined as Simpson Grade III-V. The extent of resection was estimated not only during the operation itself but also on MRI, which was performed immediately after surgery. Recurrence was defined as the presence of new tumor in patients with a completely resected tumor, as judged on the first postoperative MR image, or as evidence of new growth of an incompletely resected tumor on serial postoperative MR images compared with the immediate postoperative MR images.
All patients had undergone preoperative MRI. Baseline postoperative MRI was performed immediately after surgery to evaluate the residual mass and then at 3-or 6-month intervals within the first 2 years. To assess tumor recurrence, serial MRI was performed at 1-to 2-year intervals in asymptomatic patients, but if mass-related symptoms or focal neurological signs developed, MRI was performed immediately. Three neuroradiologists individually conducted radiological reviews to characterize tumors and to determine the presence of a recurrence without any clinical or pathological information on the patients.
Therapeutic Strategies for Atypical Meningioma
Surgical indications for meningioma were as follows: 1) tumor producing neurological symptoms, 2) growing tumor observed during regular follow-up, 3) tumor with a size of 3 cm or more, and 4) tumor requiring a differential diagnosis from other malignancies. Patients with completely resected atypical meningiomas who do not receive radiation therapy are closely observed at our institutions. We recommend postoperative radiation therapy in all patients with atypical meningiomas that are not completely resected. At the same time, as we have already mentioned, although postoperative radiotherapy is commonly applied for the remnant atypical meningioma, strong agreement for this course of action has not been established. In cases of recurrent meningiomas, reoperation should be considered as the first choice. Gamma Knife radiosurgery is an alternative treatment modality for small or surgically inaccessible meningiomas and in patients of advanced age or with a high operative risk. Patients who underwent incomplete resection of the tumor were treated with 3D conformal radiotherapy. Total irradiation dose ranged from 50 to 60 Gy (2 Gy per fraction a day, 5 fractions a week), depending on the decision of the radiation oncologist.
Immunohistochemical Staining
All tissue specimens were examined for cell-cycle regulatory proteins (p16, p15, p21, p27, CDK4, CDK6, pRB protein, and cyclin D1) and proliferative markers (MIB-1 antigen, mitosis, and p53). For this analysis, the labeled streptavidin-biotin method was performed on sections from paraffin-embedded tissues that had been used for pathological diagnoses. The following monoclonal or polyclonal primary antibodies were used: p16 (1:100, Neomark), p15 (1:100, Dako), p21 (1:100, Neomark), p27 (1:100, Neomark), CDK4 (1:100, Santa Cruz), CDK6 (1:100, Santa Cruz), pRB (1:75, Life Technology), cyclin D1 (1:100, Neomark), MIB-1 antigen (1:100, Immunotech), and p53 (1:100 Neomark).
Analysis and Interpretation of Immunoreactivity
Appropriate positive and negative controls were used throughout the study. Negative controls were obtained by omitting the primary antibody. Sections from normal meninges obtained from autopsy specimens were used as the positive control for p16, p15, p21, p27, CDK4 and 6, pRB protein, and cyclin D1. Ten fields were selected from the regions with the highest concentrations of immunopositive nuclei and examined at high power magnification (×400). Each field corresponded to a total number of cells ranging from 700 to 1000 in relation to the cellularity of the tumor specimen. Areas of necrosis, normal meningeal cells, and endothelial cells were excluded from the evaluation. On considering 1000 cells by manual counting, the immunoreactivity of proteins and markers was described as the percentage of immunopositive cells. Mitoses were counted on slides stained with H & E. The mitotic index was defined as the number of mitoses per 10 hpf. Two different neuropathologists (E. H. Lee and D. C. Kim), who were blinded to patient clinical and radiological information, reviewed all slides. There was only one discordant case (1.5%) in both reviews of immunoreactivity, and its immunoreactivity was determined after discussion. Digital images were captured using a microscope (model BX41TF, Olympus) and digital camera (model DP70, Olympus).
The purpose of analyzing the immunoreactivity of cell cycle regulators and proliferative markers was to determine whether these markers have an effect on the recurrence of atypical meningiomas. Therefore, we performed receiver operating characteristic (ROC) curve analysis on the immunoreactivity of the cell-cycle regulatory proteins and proliferative markers to predict the likelihood of recurrence. 11 We tried to determine the threshold of immunoreactivity to the highest possible sensitivity and specificity. Through sensitivity-specificity analysis, the cutoff value (the point at which sensitivity and specificity cross) was determined for each marker, as correlated with recurrence (Table 1 ). In fact, in the autopsy specimen, all of the cell-cycle regulatory proteins and proliferative markers were immunohistochemically stained below the cutoff value that we had determined. Therefore, based on the cutoff value for the immunoreactivity of each marker, sequential correlation analysis with the recurrence of atypical meningioma was performed.
Statistical Analysis
Differences between subgroups were analyzed using the Student t-test for normally distributed continuous values and the Mann-Whitney U-test for nonnormally distributed continuous values. The chi-square test was used to analyze categorical variables. To define the cutoff value, the performance of each cell-cycle regulatory protein and proliferative marker as a prognostic factor for the recurrence of atypical meningioma was investigated using ROC curve analysis and sensitivity-specificity analysis. Recurrence-free survival (RFS) was calculated according to the Kaplan-Meier method, and comparisons between groups were performed using log-rank tests. Variables found to be significantly associated with the recurrence of atypical meningiomas in the univariate analyses were then subjected to multivariate analyses. Moreover, several additional variables that have been associated with the recurrence of atypical meningioma in the literature and that we have been interested in were also subjected to multivariate analysis. In the multivariate analysis, the Cox proportional-hazards regression model was used to assess the independent effects of specific factors on the tumor recurrence rate and to define the hazard ratios for significant covariates. Two-sided p values below 0.05 were considered statistically significant. SPSS version 12.0 (SPSS Inc.) was used for the statistical analysis.
Results
Patient and Tumor Characteristics
From a total of 353 meningioma cases in the defined study period, 67 atypical meningioma patients (39 female, 28 male) were eligible for our analysis. The mean age at diagnosis for these patients was 56.6 years (range 26.4-87.2 years). Sixty-three of the patients (94.0%) had clinical symptoms before diagnosis. The most frequent chief complaints at presentation were headache ( Table 2 ).
Recurrences
The mean follow-up time from the date of resection was 47.7 months (range 8.4-132.1 months). During follow-up, 26 patients (38.8%) presented with recurrence, all cases occurring more than 1 year postsurgery. The mean time to recurrence was 61.8 months (range 15.6-111.1 months). The actual 5-and 10-year RFSs were 67.8% and 28.3%, respectively. All recurrences occurred at the original site of surgery, and there was no distant metastasis extracranially.
In terms of the clinical and radiological characteristics, recurrence occurred in 15 (39.5%) of the 38 patients who were 60 years of age or younger, 13 (46.4%) of the 28 male patients, 16 (42.1%) of the 38 patients whose tumor had a nonconvexity location, 12 (46.2%) of the 26 patients who had a tumor size ≥ 5 cm, 10 (47.6%) of the 21 patients who had a tumor with peritumoral edema ≥ 3 cm, 19 (61.3%) of the 31 patients who underwent incomplete resection, and 22 (45.8%) of the 48 patients who did not receive postoperative radiotherapy (Table 3) . Among these characteristics, there was a statistically significant difference in the recurrence rate according to the extent of resection and the presence of postoperative radiotherapy (p < 0.001 and p = 0.042, respectively, chi-square test). There was also a statistically significant difference in the time to recurrence according to the extent of resection and postoperative radiotherapy (p = 0.001 and p = 0.022, respectively, Mann-Whitney U-test). Kaplan-Meier survival analysis for RFS also showed statistically significant differences in the extent of resection (complete vs incomplete: p = 0.002, log-rank test; Fig. 1A ) and postoperative radiotherapy (yes vs no: p = 0.022, log-rank test).
In terms of cell-cycle regulatory protein, a statistically significant, higher recurrence rate was found (chisquare test) in immunohistochemical understaining for p16 (p = 0.004), overstaining for CDK6 (p = 0.013), and overstaining for pRB protein (p < 0.001). Likewise, there was also a statistically shorter time to recurrence in immunohistochemical understaining for p16 (p < 0.001), overstaining for CDK6 (p < 0.001), and overstaining for pRB protein (p = 0.002), using the Mann-Whitney U-test (Table 3) . Kaplan-Meier survival analysis for RFS also showed statistically significant differences in immunohistochemical overstaining versus understaining for p16 (p < 0.001, log-rank test), CDK6 (p < 0.001, log-rank test), and pRB protein (p = 0.001, log-rank test; Fig. 1B-D) .
All proliferative markers showed that immunohistochemical overstaining had a statistically higher recurrence rate (p < 0.05, chi-square test) and a shorter time to recurrence (p < 0.05, Mann-Whitney U-test; Table 3 ). Kaplan-Meier survival analysis for RFS also showed statistically significant differences in immunohistochemical overstaining versus understaining for MIB-1 antigen (p = 0.007, log-rank test) and p53 protein (p = 0.021, log-rank test) and in the mitotic index (p = 0.013, log-rank test).
Univariate Analysis of Factors Predicting Recurrence of Atypical Meningioma
In terms of the clinical characteristics, incomplete resection (p < 0.001) and the lack of postoperative radiotherapy (p = 0.030) were both associated with recurrence (Table 4 ). For the cell-cycle regulatory proteins, univariate analysis showed that immunohistochemical understaining for p16 (p < 0.001) and p21 (p = 0.039) were associated with tumor recurrence. Immunohistochemical overstaining for CDK4 (p = 0.033), CDK6 (p = 0.048), pRB protein (p < 0.001), and cyclin D1 (p = 0.035) were also directly associated with recurrence. In terms of proliferative markers, analysis showed that immunohistochemical overstaining for MIB-1 antigen (p = 0.019), the mitotic index (p = 0.022), and p53 (p = 0.041) were associated with recurrence.
Multivariate Analysis of Factors Predicting Recurrence of Atypical Meningioma
Multivariate analysis showed that the following factors were independently associated with a higher rate of recurrence: incomplete resection (HR 4.513, p < 0.001; Table 5 ); immunohistochemical understaining for p16 (HR 3.214, p < 0.001); immunohistochemical overstaining for CDK6 (HR 3.427, p < 0.001), pRB protein (HR 2.854, p = 0.008), and p53 (HR 2.296, p = 0.040); and increased MIB-1 antigen (HR 2.665, p = 0.013) and number of mitoses (≥ 8/10 hpf; HR 2.438, p = 0.024).
The factors associated with recurrence in the univariate analysis but not independently associated with a higher rate of recurrence in the multivariate analysis were as follows: no postoperative radiotherapy (p = 0.058); immunohistochemical understaining for p21 (p = 0.054), immunohistochemical overstaining for CDK4 (p = 0.112), and immunohistochemical overstaining for cyclin D1 (p = 0.274). Other factors of interest, such as p15 (p = 0.157) and p27 (p = 0.326), were not associated on multivariate analysis (Table 5 ).
Discussion
The purpose of this study was to evaluate the role of cell-cycle regulatory proteins in the recurrence of atypical meningiomas using immunohistochemical staining analysis. To the best of our knowledge, the present study is the largest work of clinical research to use immunohistochemical staining to assess the role of cell-cycle regulatory proteins in the recurrence of atypical meningiomas. Although there was a study showing that p16, CDK6, and pRB were differentially expressed in meningioma cell cultures with a 20-, 30-, and 36-fold difference between the lowest and highest levels of each protein, respectively, that work did not suggest any clinical association. 2 Interestingly, this study showed that immunohistochemical staining results for some cell-cycle regulatory proteins (p16, CDK6, pRB) predict the recurrence of atypical meningiomas. In fact, the protein p16 has been noted with regard to potential new prognostic markers for meningiomas. It is encoded by the tumor suppressor gene CD-KN2A and is a CDK inhibitor involved in cell cycle arrest via p53-independent mechanisms. One of the mechanisms held responsible for malignant progression in meningiomas is the loss of chromosome 9p, which harbors CDKN2A. Recent publications have reported high frequencies of genetic and epigenetic aberrations of p16 in meningiomas. 36, 47 CDKN2A deletions have been particularly observed in malignant meningiomas and have been correlated with shortened survival. 5, 36, 43 On the other hand, Barker et al. 4 were unable to demonstrate p16 loss in their meningioma cases. Results of the only other immunohistochemical study on p16 in meningiomas are in line with the theory of malignant progression and CDKN2A loss, as the data indicated high p16 positivity in benign forms and those without recurrence. 22 However, there is a report suggesting a result in opposition to ours in terms of the expression of p16: Terzi et al. 46 reported that Ki 67 and p53 labeling indices as well as overexpression of p16 were strongly associated with decreased RFS in a univariate analysis. In their study, the fact that immunohistochemical overexpression of Ki 67 and p53 were factors predicting meningioma recurrence agrees with our results, whereas their finding that the immunohistochemical overexpression of p16 predicts recurrence in meningiomas directly opposes our results. Note, however, that their immunohistochemical analysis was focused on histological grading of the meningioma, and thus benign, atypical, and malignant meningiomas were all included in their study. Furthermore, their cutoff value for the overexpression of p16 was 10%, which was different from our cutoff of 27%. Additionally, they did not exclude cytoplasmic staining of p16. Because it is a CDK inhibitor, p16 is presumed to function in the nucleus, which is where it is located in normal cells. Cytoplasmic staining is therefore considered nonspecific or controversial. In our study, only nuclear staining for p16 was considered. Therefore, it is impossible for us to make a direct comparison with our results.
In fact, the prognostic role of cell-cycle regulatory proteins and proliferative markers has been established for several cancer types. In particular, several studies have documented the role of RB protein in the prognosis and progression of malignant brain tumors such as glioblastoma. 7, 14, 16 Among these works, the study by Hilton et al. 16 suggested that glioblastomas showing widespread immunohistochemical expression of RB protein have a better prognosis than those without this feature, which is different from our results. However, the authors did not separate RB protein into phosphorylated and unphosphorylated forms. Thus, the data from unphosphorylated RB proteins were intermingled with those from pRB proteins, which accounts for the different results. As mentioned earlier, pRB protein is important for transit into the S phase in the cell cycle. Therefore, interpretation of their results is limited. Clinically, recurrence rates vary between studies, depending on both the duration of follow-up and the number of patients studied. An analysis of some of these studies has shown that the patient's age at diagnosis, 20 complete resection or GTR, 30 and postoperative radiotherapy 20, 33 are invariably associated with lower risks of atypical meningioma recurrence.
As regards the extent of resection, which is a significant independent predictive factor of recurrence in atypical meningiomas as well as in meningiomas overall, many authors have reported similar results. The RFS rates have been reported as 62%-93% at 5 years after GTR and 25%-63% after subtotal resection. 15, 18, 28 Results in the present study-those obtained through KaplanMeier survival analysis and the Cox proportional-hazards regression model-correspond well with these findings, suggesting that the most important factor in determining the likelihood of meningioma recurrence is the extent of tumor resection.
In this study, postoperative radiotherapy was not an independent factor predicting the recurrence of atypical meningiomas in the multivariate analysis (Cox proportional-hazards regression model), and it showed only a tendency to predict a recurrence (p = 0.058). However, statistically significant, lower recurrence rates (chi-square test) and a longer time to recurrence (Mann-Whitney Utest and log-rank test) were found in the atypical meningioma patients who had received postoperative radiotherapy. In fact, many authors advocate adjuvant radiotherapy for the treatment of malignant meningiomas regardless of the extent of resection because of the extremely high rate of local recurrence. 10, 40 However, the optimal treatment for atypical meningiomas is still controversial. Atypical meningiomas are rare tumors often integrated with benign or malignant histologies when analysis is performed. A few studies have reported the outcomes and prognostic factors for solitary atypical meningiomas, but the results are inconsistent. 1, 20, 26 Some investigators favor the early addition of postoperative radiotherapy even after GTR to achieve better local control. 1, 20 Others argue that the role of postoperative radiotherapy remains unclear. 26, 44 Therefore, more data are essential to establish the optimum postoperative treatment in patients with atypical meningioma. Despite inconsistent reports regarding the benefit of postoperative radiotherapy in atypical meningioma, a combined treatment approach using resection followed by postoperative radiotherapy has been commonly applied given this tumor type's high recurrence rate and poor prognosis. As shown in our results, the completeness of resection is a well-known prognosticator of the local recurrence of high-risk meningiomas.
Despite the contributions this study makes to the literature, it has several limitations. First, its main limitation is the inherent bias introduced by its retrospective nature. Indeed, it is difficult to provide sufficient statistical power from such a small number of patients (26) with a recurrence to prove reliable results. We attempted to reduce this bias by collecting patient data from complete medical and radiological records and by recruiting patients who had been treated using the same protocol. Although the pathological slides and radiological images were independently reviewed by multiple investigators, without any information on the patients to reduce the bias, we cannot say clearly that no bias originated from this retrospective study. Thus, to improve this weakness, the conclusions drawn from our data need further validation through prospective and randomized clinical trials in a larger number of cases.
Second, we analyzed the cell cycle regulators only at the protein level by using immunohistochemical staining. Although the molecular and genetic alterations underlying the progression of meningiomas are still poorly understood, cytogenetic studies have indicated that atypical and anaplastic meningiomas frequently show complex numerical and structural aberrations involving several chromosomes associated with cell cycle regulators. Therefore, given our limited focus on cell-cycle regulatory proteins, our study cannot explain all the mechanisms in the genetic and molecular biological processes involved. Third, we did not deal with neurofibromatosis in these meningiomas. However, accompanying conditions, such as neurofibromatosis Type 2 (NF2), can also contribute to prognosis. Patients with NF2 are known to have meningiomas at a relatively younger age and an increased chance of multicentricity, findings that have been confirmed by subsequent research. 46 Moreover, a higher incidence of NF2 has been reported in patients with WHO Grade II and III meningiomas. 37 Perry et al. also noted a higher incidence of atypical and malignant meningiomas in patients with NF2. Another interesting finding from the Perry study was the greater loss of p16 in patients with NF; that is, 70% of NF cases showed p16 loss. Nevertheless, we did not exclude the possibility of interference by NF2 in our cases.
The fourth limitation is that we did not examine all the cell-cycle regulatory proteins that may be implicated. The cell-cycle control system is a cyclical biochemical device constructed from a set of interacting proteins that induce and coordinate proper progression through the cycle, and includes the cyclins, CDKs, and their CDK inhibitors. However, we studied a specific aspect of the cellcycle control system, especially the transmission from G1 to the S phase. This may have biased the interpretation of our results, because some interactions between regulatory proteins were not considered.
Finally, despite the interpretation of sample immunoreactivity by two different neuropathologists, we are unsure if the results are absolutely correct because the interpretation of many immunohistochemical stains is qualitative and subjective. Proper interpretation of most immunohistochemical stains depends to some extent on estimating antigen content and in establishing cutoff levels between positive and negative results. Reasonable reproducibility from run to run is essential for these cutoff levels to work. Additionally, threshold levels require adjustment to methodology, in particular to method sensitivity. For this reason, we used specificity-sensitivity testing to determine the optimal cutoff level. However, to ensure reproducibility, additional studies are necessary.
Conclusions
In this study, we investigated the prognostic value of several cell-cycle regulatory proteins in predicting the recurrence of atypical meningiomas after resection. We found that p16, CDK6, and pRB protein are associated with the recurrence of atypical meningiomas. We also confirmed that proliferative markers, such as the MIB-1 labeling index, mitotic index, and p53, have a significant association with the recurrence of atypical meningiomas. Additionally, incomplete resection was associated with a higher recurrence rate. Nonetheless, further studies using sophisticated and systemically developed molecular biology techniques are required to examine this meningioma subtype further, especially to characterize the genetic process underlying the recurrence of atypical meningiomas.
